^
Association details:
| Biomarker: | MTA2 overexpression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Melatonin combined with sorafenib synergistically inhibit the invasive ability through targeting metastasis-associated protein 2 expression in human renal cancer cells
Published date:
10/21/2021
Excerpt:
Human renal cancer cell lines (Caki-1 and ACHN) were treated with melatonin combined with sorafenib were detected the cell growth and cell cycle...Meier survival analyses, to find that high MTA2 expression in RCC patients had a significantly lower survival rate compared with low MTA2 expression in RCC patients [P < 0.001...
DOI:
10.4103/tcmj.tcmj_204_21